Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Targeted Cancer Therapies02:57

Targeted Cancer Therapies

7.1K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
7.1K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

2.7K
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
2.7K
Clinical Trials01:16

Clinical Trials

8.5K
Clinical trials are prospective experimental studies conducted on humans to determine the safety and efficacy of treatments, drugs, diet methods, and medical devices. Using statistics in clinical trials enables researchers to derive reasonable and accurate conclusions from the collected data, allowing them to make wise decisions in uncertain situations. In medical research, statistical methods are crucial for preventing errors and bias.
There are four phases in a clinical trial. A phase one...
8.5K
Clinical Trials: Overview01:11

Clinical Trials: Overview

4.7K
Clinical development focuses on how the drug will interact with the human body and encompasses four key phases of clinical trials, each serving a specific purpose in assessing the safety and effectiveness of new drugs. These phases overlap and build upon one another. Phase I involves a small group of healthy volunteers (typically 20-80 individuals) or, in cases where significant toxicity is expected, patients with the targeted disease, such as cancer or AIDS. The volunteers are tested for...
4.7K
Tumor Immunotherapy01:27

Tumor Immunotherapy

2.6K
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.
2.6K
  1. Home
  3. Final Results From A Phase I Trial And Expansion Cohorts Of Cabozantinib And Nivolumab Alone Or With Ipilimumab For Advanced/metastatic Genitourinary Tumors.
  1. Home
  3. Final Results From A Phase I Trial And Expansion Cohorts Of Cabozantinib And Nivolumab Alone Or With Ipilimumab For Advanced/metastatic Genitourinary Tumors.

Related Experiment Video

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K

Final Results From a Phase I Trial and Expansion Cohorts of Cabozantinib and Nivolumab Alone or With Ipilimumab for

Andrea B Apolo1, Daniel M Girardi1, Scot A Niglio1

  • 1Genitourinary Malignancies Branch, Center for Cancer Research, National Cancer Institute, National Institutes of Health, Bethesda, MD.

Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology
|July 2, 2024

View abstract on PubMed

Summary
This summary is machine-generated.

More Related Videos

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Related Experiment Videos

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
04:04

Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer

Published on: February 12, 2017

10.5K
A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer
07:25

A Bioluminescent and Fluorescent Orthotopic Syngeneic Murine Model of Androgen-dependent and Castration-resistant Prostate Cancer

Published on: March 6, 2018

13.1K
Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment
07:29

Intramucosal Inoculation of Squamous Cell Carcinoma Cells in Mice for Tumor Immune Profiling and Treatment Response Assessment

Published on: April 22, 2019

11.5K

Cabozantinib plus nivolumab, with or without ipilimumab, shows efficacy in genitourinary cancers. This combination therapy demonstrated clinical activity and manageable safety in patients with metastatic urothelial carcinoma and renal cell carcinoma.

Area of Science:

  • Genitourinary (GU) oncology
  • Cancer immunotherapy
  • Targeted cancer therapy

Background:

  • Metastatic urothelial carcinoma (mUC) and metastatic renal cell carcinoma (mRCC) have limited treatment options.
  • Cabozantinib and nivolumab (CaboNivo) ± ipilimumab (CaboNivoIpi) are novel treatment strategies.
  • Phase I data suggested promising efficacy and safety in GU malignancies.

Purpose of the Study:

  • To report final safety, overall response rate (ORR), progression-free survival (PFS), and overall survival (OS) from a phase I trial.
  • To evaluate CaboNivo and CaboNivoIpi in mUC, mRCC, and rare GU tumors.
  • To analyze data from phase I patients and seven expansion cohorts.

Main Methods:

  • Investigator-initiated, multicenter, phase I trial.
  • Expansion cohorts for CaboNivo doublet (mUC, mRCC, bladder adenocarcinoma) and CaboNivoIpi triplet (mUC, mRCC, penile cancer, rare GU tumors).
  • Enrollment of 120 patients; median follow-up of 49.2 months.

    • Main Results:

    • Overall Response Rate (ORR) was 38% (11% complete response) with a median duration of response of 20 months.
    • High ORRs observed in specific GU malignancies: mUC (42.4%), mRCC (62.5%), squamous cell carcinoma of the bladder (85.7%), penile cancer (44.4%).
    • Grade ≥ 3 treatment-related adverse events occurred in 84% (CaboNivo) and 80% (CaboNivoIpi) of patients.

    Conclusions:

    • Cabozantinib and nivolumab, alone or with ipilimumab, demonstrate clinical activity and acceptable safety in GU malignancies.
    • The combination therapy is particularly effective in clear cell RCC, urothelial carcinoma, and rare GU tumors.
    • Further investigation in larger trials is warranted for these promising treatment regimens.